Galapagos to supply chemical compound sets to Johnson & Johnson Pharmaceutical Research & Development, Division of Janssen Pharm

    Mechelen, Belgium; 8 March 2007 - Galapagos NV (Euronext & LSE: GLPG)
announced today that its service division, BioFocus DPI, has  entered
into an  agreement  to  supply  small  molecule  compounds  for  drug
discovery  to  the  Johnson  &  Johnson  Pharmaceutical  Research   &
Development Division of Janssen Pharmaceutica NV (J&JPRD).  Under the
terms of the two-year agreement, BioFocus DPI will provide access  to
compounds from its SoftFocus small  molecule libraries and will  also
generate customer specific compound library sets for use in  J&JPRD's
drug discovery programs.  Financial terms were not disclosed.

"This supply agreement is a  natural expansion of our drug  discovery
relationship with  J&JPRD.   It  will give  J&JPRD access  to  highly
targeted drug  building blocks  for their  drug discovery  programs,"
said Onno van de Stolpe, Chief Executive Officer of Galapagos.


About Galapagos
Galapagos (Euronext Brussels, GLPG; Euronext Amsterdam, GLPGA; London
AiM: GLPG) is a drug discovery company with clinical and pre-clinical
programs in bone and joint diseases, cachexia, and menopausal hot
flashes.  Its division BioFocus DPI offers a full suite of
target-to-drug discovery products and services to pharmaceutical and
biotech companies, encompassing target discovery and validation,
screening and drug discovery through to delivery of pre-clinical
candidates.  BioFocus DPI also provides adenoviral reagents for rapid
identification and validation of novel drug targets, compound
libraries for drug screening as well as chemogenomics and ADMET[1]
database products to select targets and compounds.  Galapagos
currently employs 450 people and operates facilities in eight
countries, with global headquarters in Mechelen, Belgium.  More
information about Galapagos and BioFocus DPI can be found at
www.glpg.com.

CONTACT

Galapagos NV
Onno van de Stolpe, CEO
Tel: [phone]
[e-mail]


This  release  may  contain  forward-looking  statements,  including,
without  limitation,  statements  containing  the  words  "believes,"
"anticipates," "expects," "intends,"  "plans," "seeks,"  "estimates,"
"may," "will,"  "could," "stands  to," and  "continues," as  well  as
similar expressions.   Such  forward-looking statements  may  involve
known and unknown risks, uncertainties and other factors which  might
cause  the  actual  results,  financial  condition,  performance   or
achievements of  Galapagos, or  industry  results, to  be  materially
different from any historic or future results, financial  conditions,
performance  or   achievements   expressed   or   implied   by   such
forward-looking statements.  Given these uncertainties, the reader is
advised not  to  place any  undue  reliance on  such  forward-looking
statements.  These  forward-looking statements speak  only as of  the
date of publication of this document.  Galapagos expressly  disclaims
any obligation to update any such forward-looking statements in  this
document to  reflect  any  change in  its  expectations  with  regard
thereto or any change in events, conditions or circumstances on which
any such statement is based, unless required by law or regulation.

SoftFocus® is a registered trademark of Galapagos NV and/or its
affiliates.

[1] ADMET is the acronym for Absorption, Distribution, Metabolism,
Excretion, and Toxicity: Meeting parameters against these five
criteria is critical to the success of a pharmaceutical compound as a
drug.






Copyright © Hugin ASA 2007. All rights reserved.